ID   SDC4_RAT                Reviewed;         202 AA.
AC   P34901;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   29-MAY-2024, entry version 163.
DE   RecName: Full=Syndecan-4 {ECO:0000305};
DE            Short=SYND4;
DE   AltName: Full=Ryudocan core protein;
DE   Flags: Precursor;
GN   Name=Sdc4 {ECO:0000312|RGD:3650}; Synonyms=Synd4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=1537865; DOI=10.1016/s0021-9258(18)42911-0;
RA   Kojima T., Shworak N.W., Rosenberg R.D.;
RT   "Molecular cloning and expression of two distinct cDNA-encoding heparan
RT   sulfate proteoglycan core proteins from a rat endothelial cell line.";
RL   J. Biol. Chem. 267:4870-4877(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8495865; DOI=10.1159/000216925;
RA   Shworak N.W., Kojima T., Rosenberg R.D.;
RT   "Isolation and characterization of ryudocan and syndecan heparan sulfate
RT   proteoglycans, core proteins, and cDNAs from a rat endothelial cell line.";
RL   Haemostasis 23:161-176(1993).
RN   [3]
RP   GLYCOSYLATION AT SER-44; SER-65 AND SER-67, AND MUTAGENESIS OF SER-44;
RP   SER-65 AND SER-67.
RX   PubMed=7520439; DOI=10.1016/s0021-9258(17)31949-x;
RA   Shworak N.W., Shirakawa M., Mulligan R.C., Rosenberg R.D.;
RT   "Characterization of ryudocan glycosaminoglycan acceptor sites.";
RL   J. Biol. Chem. 269:21204-21214(1994).
CC   -!- FUNCTION: Cell surface proteoglycan which regulates exosome biogenesis
CC       in concert with SDCBP and PDCD6IP. {ECO:0000250|UniProtKB:P31431}.
CC   -!- SUBUNIT: Homodimer. Interacts with CDCP1 and SDCBP (By similarity).
CC       Interacts (via its cytoplasmic domain) with GIPC (via its PDZ domain).
CC       Interacts (via its cytoplasmic domain) with NUDT16L1 (By similarity).
CC       Interacts with DNM2; this interaction is markedly enhanced at focal
CC       ahesion site upon induction of focal adhesions and stress-fiber
CC       formation (By similarity). {ECO:0000250|UniProtKB:O35988,
CC       ECO:0000250|UniProtKB:P31431}.
CC   -!- INTERACTION:
CC       P34901; P04937: Fn1; NbExp=2; IntAct=EBI-1173182, EBI-6127274;
CC       P34901; P05696: Prkca; NbExp=3; IntAct=EBI-1173182, EBI-935801;
CC       P34901; P34900: Sdc2; NbExp=4; IntAct=EBI-1173182, EBI-1173032;
CC       P34901; P34901: Sdc4; NbExp=3; IntAct=EBI-1173182, EBI-1173182;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255}; Single-pass type I
CC       membrane protein {ECO:0000255}. Secreted
CC       {ECO:0000250|UniProtKB:P31431}. Note=Shedding of the ectodomain
CC       produces a soluble form. {ECO:0000250|UniProtKB:P31431}.
CC   -!- PTM: Shedding is enhanced by a number of factors such as heparanase,
CC       thrombin or EGF. Also by stress and wound healing. PMA-mediated
CC       shedding is inhibited by TIMP3 (By similarity).
CC       {ECO:0000250|UniProtKB:P31431}.
CC   -!- PTM: O-glycosylated; contains both chondroitin sulfate and heparan
CC       sulfate (PubMed:7520439). Ser-44, Ser-65 and Ser-67 can all be modified
CC       by either chondroitin sulfate or heparan sulfate, and the protein
CC       exists in forms that contain only chondroitin sulfate, only heparan
CC       sulfate and both chondroitin sulfate and heparan sulfate
CC       (PubMed:7520439). {ECO:0000269|PubMed:7520439}.
CC   -!- SIMILARITY: Belongs to the syndecan proteoglycan family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M81786; AAA73167.1; -; mRNA.
DR   EMBL; S61868; AAB26725.1; -; mRNA.
DR   PIR; A42410; A42410.
DR   RefSeq; NP_036781.1; NM_012649.2.
DR   PDB; 5A2P; X-ray; 2.50 A; E/F/G/H=195-202.
DR   PDB; 5G1D; X-ray; 2.81 A; C/D=195-202.
DR   PDBsum; 5A2P; -.
DR   PDBsum; 5G1D; -.
DR   AlphaFoldDB; P34901; -.
DR   BMRB; P34901; -.
DR   SMR; P34901; -.
DR   BioGRID; 246895; 2.
DR   IntAct; P34901; 7.
DR   MINT; P34901; -.
DR   STRING; 10116.ENSRNOP00000019386; -.
DR   GlyCosmos; P34901; 3 sites, No reported glycans.
DR   GlyGen; P34901; 3 sites.
DR   iPTMnet; P34901; -.
DR   PhosphoSitePlus; P34901; -.
DR   PaxDb; 10116-ENSRNOP00000019386; -.
DR   Ensembl; ENSRNOT00000019386.4; ENSRNOP00000019386.2; ENSRNOG00000014297.4.
DR   Ensembl; ENSRNOT00055006674; ENSRNOP00055005109; ENSRNOG00055004177.
DR   Ensembl; ENSRNOT00060001705; ENSRNOP00060000920; ENSRNOG00060001202.
DR   Ensembl; ENSRNOT00065045161; ENSRNOP00065037041; ENSRNOG00065026184.
DR   GeneID; 24771; -.
DR   KEGG; rno:24771; -.
DR   UCSC; RGD:3650; rat.
DR   AGR; RGD:3650; -.
DR   CTD; 6385; -.
DR   RGD; 3650; Sdc4.
DR   eggNOG; ENOG502S1SZ; Eukaryota.
DR   GeneTree; ENSGT00940000160663; -.
DR   HOGENOM; CLU_046599_3_0_1; -.
DR   InParanoid; P34901; -.
DR   OMA; WVPTEPK; -.
DR   OrthoDB; 4258425at2759; -.
DR   PhylomeDB; P34901; -.
DR   TreeFam; TF320463; -.
DR   Reactome; R-RNO-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-RNO-2022928; HS-GAG biosynthesis.
DR   Reactome; R-RNO-2024096; HS-GAG degradation.
DR   Reactome; R-RNO-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-RNO-3000170; Syndecan interactions.
DR   Reactome; R-RNO-975634; Retinoid metabolism and transport.
DR   PRO; PR:P34901; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000014297; Expressed in kidney and 20 other cell types or tissues.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0043034; C:costamere; IDA:RGD.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001968; F:fibronectin binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005080; F:protein kinase C binding; IDA:RGD.
DR   GO; GO:0070053; F:thrombospondin receptor activity; ISO:RGD.
DR   GO; GO:0007155; P:cell adhesion; NAS:RGD.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007267; P:cell-cell signaling; NAS:RGD.
DR   GO; GO:0060122; P:inner ear receptor cell stereocilium organization; ISO:RGD.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; ISO:RGD.
DR   GO; GO:0001843; P:neural tube closure; ISO:RGD.
DR   GO; GO:1903543; P:positive regulation of exosomal secretion; ISO:RGD.
DR   GO; GO:1903553; P:positive regulation of extracellular exosome assembly; ISO:RGD.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:RGD.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IMP:RGD.
DR   GO; GO:0010762; P:regulation of fibroblast migration; ISO:RGD.
DR   GO; GO:0001657; P:ureteric bud development; IEP:RGD.
DR   GO; GO:0042060; P:wound healing; ISO:RGD.
DR   InterPro; IPR003585; Neurexin-like.
DR   InterPro; IPR001050; Syndecan.
DR   InterPro; IPR027789; Syndecan/Neurexin_dom.
DR   InterPro; IPR030479; Syndecan_CS.
DR   PANTHER; PTHR10915; SYNDECAN; 1.
DR   PANTHER; PTHR10915:SF3; SYNDECAN-4; 1.
DR   Pfam; PF01034; Syndecan; 1.
DR   SMART; SM00294; 4.1m; 1.
DR   PROSITE; PS00964; SYNDECAN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Glycoprotein; Heparan sulfate;
KW   Membrane; Proteoglycan; Reference proteome; Secreted; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..202
FT                   /note="Syndecan-4"
FT                   /id="PRO_0000033513"
FT   TOPO_DOM        24..149
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        150..174
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        175..202
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          42..76
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          89..138
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        52..69
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        105..126
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        44
FT                   /note="O-linked (Xyl...) (glycosaminoglycan) serine"
FT                   /evidence="ECO:0000269|PubMed:7520439"
FT   CARBOHYD        65
FT                   /note="O-linked (Xyl...) (glycosaminoglycan) serine"
FT                   /evidence="ECO:0000269|PubMed:7520439"
FT   CARBOHYD        67
FT                   /note="O-linked (Xyl...) (glycosaminoglycan) serine"
FT                   /evidence="ECO:0000269|PubMed:7520439"
FT   MUTAGEN         44
FT                   /note="S->T: Reduced glycosaminoglycan attachment."
FT                   /evidence="ECO:0000269|PubMed:7520439"
FT   MUTAGEN         65
FT                   /note="S->T: Reduced glycosaminoglycan attachment."
FT                   /evidence="ECO:0000269|PubMed:7520439"
FT   MUTAGEN         67
FT                   /note="S->T: Reduced glycosaminoglycan attachment."
FT                   /evidence="ECO:0000269|PubMed:7520439"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:5A2P"
SQ   SEQUENCE   202 AA;  21962 MW;  5D9C8B3BF4C0D58A CRC64;
     MAPVCLFAPL LLLLLGGFPV APGESIRETE VIDPQDLLEG RYFSGALPDD EDAGGLEQDS
     DFELSGSGDL DDTEEPRTFP EVISPLVPLD NHIPENAQPG IRVPSEPKEL EENEVIPKRV
     PSDVGDDDVS NKVSMSSTSQ GSNIFERTEV LAALIVGGVV GILFAVFLIL LLVYRMKKKD
     EGSYDLGKKP IYKKAPTNEF YA
//
